NCT03806101 is a Phase 1 clinical trial of PF-04965842 in Healthy, sponsored by Pfizer.

Who is sponsoring NCT03806101?

NCT03806101 is sponsored by Pfizer.

What drugs are being tested in NCT03806101?

Interventions in NCT03806101: PF-04965842, Rosuvastatin.

Is NCT03806101 still recruiting?

NCT03806101 is currently completed. Last updated 6 May 2019.

Last reviewed 2019-05-06 · How we verify

NCT03806101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

Completed Phase 1 Last updated 6 May 2019

What this trial tests

Phase 1 trial testing PF-04965842 in Healthy in 12 participants. Completed in 11 April 2019.

Timeline

23 January 2019

Primary endpoint
15 March 2019

11 April 2019

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	23 January 2019
Primary completion	15 March 2019
Estimated completion	11 April 2019
Sites	1 location across Belgium

Drugs / interventions tested

PF-04965842 — full drug profile →
Rosuvastatin (rosuvastatin) — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of PF 04965842 on rosuvastatin PK in healthy participants. Participants will be randomized to 1 of the 2 treatment sequences. A total of approximately 12 healthy male and/or female participants will be enrolled in the study so that approximately 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods. In both sequences, participants will remain in the CRU for a total of 11 days and 10 nights (including Period 1 and Period 2). To adequately remove any drug effects of rosuvastatin from Period 1 to Period 2, there will be a minimum 5 day washout period between the 2 rosuvastatin dosing events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Vourvahis M, Byon W, Chang C, Le V, et al · · 2022 · cited 13× · PMID 35344588 · DOI 10.1002/cpt.2594

Verify or expand the search:

Other trials of PF-04965842

Trials testing the same drug.

NCT04099563 — Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants · Phase 1 · completed
NCT03937258 — A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants · Phase 1 · completed
NCT03796676 — JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis · Phase 3 · completed
NCT03796182 — Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants · Phase 1 · completed
NCT03742336 — Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03806101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 6 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03806101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing